Latest Ras subfamily Stories
Company leveraging the scalability of its proprietary platform and next generation sequencing to introduce a full line of multiplexed urine-based oncogene mutation assays with superb sensitivity
Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014
ACA is Changing How Some Businesses Can Use HRAs in 2014 Park City, Utah (PRWEB) January 21, 2014 Today, Zane Benefits, the #1 Online Health Benefits
In the study by Toulany et al., it was demonstrated for the first time that long term treatment with inhibitors of PI3K (as it is performed clinically) results in a reactivation of the major survival component Akt through a so far unknown regulatory loop via ERK1/2.
Scientists have described a new family of proteins that appear to play a key role in cancer and might be targets for future cancer drugs.
Despite recent regulations, stand-alone HRAs are still a go for one-person plan Park City, Utah (PRWEB) November 12, 2013 Today, Zane Benefits, the number
Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex.